Galectin Therapeutics Inc.
GALTGalectin Therapeutics Inc. (GALT) is a biotechnology company focused on developing therapies that target galectin proteins, which play a role in fibrosis, inflammation, and cancer. Their primary pathways involve developing drugs to treat various fibrotic and immune-related conditions, including non-alcoholic steatohepatitis (NASH) and other liver diseases. The company leverages its expertise in galectin biology to advance novel therapeutics aimed at addressing unmet medical needs.
Company News
Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.
Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable inside...
